PPARG and neoplasm: Based on mouse models constructed from the colon cancer cell line CT26 and breast cancer cell line 4T1, the PPARγ agonist rosiglitazone was found to remodel the tumor vasculature system and limit tumor-associated macrophage (TAM) infiltration.